Cresco Labs Secures $50M Revolving Credit Facility

CHICAGO – Cresco Labs Inc. announced the closing of a credit agreement with Needham Bank, giving the company access to a $50 million revolving credit facility. The facility carries a fixed interest rate of 7.99% and remains available through August 2030.

Borrowings under the facility can be used to fund growth initiatives, acquisitions, and general corporate purposes. CEO Charlie Bachtell framed the deal in terms of both strategic flexibility and capital market ambitions:

“Access to conventional bank capital gives us a powerful, nondilutive tool to accelerate our strategy,” Bachtell said. “As demonstrated by our recent Pennsylvania acquisition, we see significant opportunities to deploy capital into assets that enhance earnings, improve margins and create long-term shareholder value. This added flexibility positions us to drive growth, strengthen our balance sheet and support Cresco as we work toward broader access to U.S. capital markets and a future uplisting to a senior exchange.”

The deal’s significance extends beyond Cresco’s own books. Compared to other industries, access to conventional banking services remains limited in the U.S. Cannabis industry. Historically, Cresco Labs and other players in Cannabis have relied on private lenders [often borrowing at high rates], sale-and-leaseback transactions, or equity raises due to ongoing federal restrictions. Getting a revolving line from a federally chartered institution, at a fixed rate below 8%, marks a meaningful departure from that norm.

The timing of the announcement is notable in its own right. Earlier in May, Cresco registered certain state-licensed medical Cannabis facilities with the DEA following the federal rescheduling of medical Cannabis to Schedule III under the Controlled Substances Act, encompassing cultivation, processing, and dispensary operations serving medical patients within its footprint. That federal registration appears to have removed a layer of compliance risk that historically gave institutional lenders pause.

This credit facility also follows Cresco’s August 2025 refinancing of its larger debt stack. The company closed a $325 million senior secured term loan at 12.5% per annum, replacing an older $360 million facility, reducing total debt and extending its maturity runway to 2030. The new revolving facility sits on top of that structure as a more flexible, lower-cost tool.

Cresco Labs operates a vertically integrated model with cultivation, production, and retail under the Sunnyside banner. It has built a portfolio of brands, maintaining leading market shares in several key states. The company has posted steady revenue, with Q1 2026 figures at $151 million and adjusted EBITDA of $33 million.

The Cannabis capital stack has long been distorted by federal prohibition. Lenders charged a risk premium, and conventional revolvers were essentially unavailable to plant-touching operators at scale. The Needham deal suggests that premium is beginning to compress, at least for the handful of MSOs that have invested years in demonstrating institutional-grade financial discipline. With cash on hand, Cresco can navigate a market that still features pricing pressure and uneven regulatory progress. Access to bank capital at a reasonable rate strengthens the balance sheet and supports longer-term goals, including potential uplisting to a senior exchange.